All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Multiple Myeloma Hub spotlight: Updated data from the phase II KarMMa-2 trial
⭐Multiple Myeloma Hub spotlight: Updated data from the phase II KarMMa-2 trial ⭐
At the European Haematology Association Congress 2024, Xavier Leleu, Poitiers University Hospital, Poitiers, FR discussed results from Cohort 2B of the phase II KarMMa-2 trial (NCT03601078) investigating the safety and efficacy of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk early-relapse multiple myeloma without frontline stem cell transplantation (N = 31). The primary endpoint of complete response rate was achieved in 71% patients, highlighting the potential for ide-cel use in earlier lines of treatment.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?